Dr. JOHANN LECHNER , Bioinformatics ,Best Researcher Award

Dr. JOHANN LECHNER , Bioinformatics ,Best Researcher Award

Dr. JOHANN LECHNER atPraxisklinik Integrative ZahnMedizin,Germany

Author Profile

 

🔬 Innovator in Jawbone Health

Dr. Lechner’s research emphasizes the significance of unresolved wound healing in the jawbone, particularly after procedures like wisdom tooth extractions. He has identified that these unhealed areas often fill with fatty degenerative osteonecrosis (FDOJ), leading to silent, chronic inflammation.

🧬 Linking FDOJ with Systemic Diseases

Dr. Lechner’s pioneering idea connects the overexpression of the chemokine RANTES/CCL5 in FDOJ to systemic inflammation, contributing to diseases such as cancer and autoimmune conditions. His work highlights the importance of recognizing and addressing these hidden jawbone infections to improve overall health outcomes.

📈 Advancements in Diagnostic Techniques

Traditional imaging methods like x-rays and CBCT/DTV often fail to detect FDOJs. Dr. Lechner’s research led to the development and validation of trans alveolar ultrasound sonography (TAU), a technique that accurately measures jawbone density and identifies FDOJs. This breakthrough has been documented in studies published in Ultrasound in Medicine and Biology.

Impact on Patient Health
Dr. Lechner’s findings reveal that removing these silent jawbone inflammations can significantly enhance the body’s healing capabilities, transforming the lives of patients suffering from chronic inflammatory conditions. His work has the potential to revolutionize dental practice and systemic disease management, offering hope to millions.

Vision for the Future
Dr. Lechner envisions a future where every dentist has the tools to diagnose and treat FDOJs, drastically reducing the prevalence of systemic diseases linked to chronic inflammation. His research and clinical practices continue to inspire the medical and dental communities to integrate Jawbone Detox into standard healthcare protocols, promoting a holistic approach to health and wellness.

Publication Top Noted:

Osteoimmune Interaction and TH-1/TH-2 Ratio in Jawbone Marrow Defects: An Underestimated Association – Original Research

Comparison of Cytokine RANTES/CCL5 Inflammation in Apical Periodontitis and in Jawbone Cavitations – Retrospective Clinical Study

Osseointegration and osteoimmunology in implantology: assessment of the immune sustainability of dental implants using advanced sonographic diagnostics: research and case reports

 Reduction of Inflammatory RANTES/CCLS Serum Levels by Surgery in Patients with Bone Marrow Defects of the Jawbone

Linking Dentistry and Chronic Inflammatory Autoimmune Diseases – Can Oral and Jawbone Stressors Affect Systemic Symptoms of Atopic Dermatitis? A Case Report

 

 

Dr .Yuan Yao, Drug Discovery and Development ,Best Researcher Award

Dr .Yuan Yao , Drug Discovery and Development ,Best Researcher Award

Dr .Yuan Yao at Peking University Cancer Hospital & Institute,China

Author Profile

🔬 Research and Innovations

Dr. Yao is actively involved in pioneering research, particularly in the field of PET/CT equipment imaging performance. This work is part of the National Key R&D Program, conducted in collaboration with Shandong University and other institutions. Additionally, Dr. Yao has led innovative projects under the Peking University Health Science Center’s “Excellent Doctoral Candidate Innovation Fund.”

📚 Citation Index

As a first author, Dr. Yao has contributed to significant advancements in medical imaging and nuclear medicine through numerous publications:

  • Construction and preclinical evaluation of a zirconium-89 labelled monoclonal antibody targeting PD-L2 in lung cancer (Biomedicine & pharmacotherapy, 2023)
  • Construction and preclinical evaluation of a (124/125)I-Labeled specific antibody targeting PD-L2 in lung cancer (Mol Pharm, 2023)
  • The role of PET molecular imaging in immune checkpoint inhibitor therapy in lung cancer (European Journal of Radiology, 2022)
  • Novel miRNA predicts survival and prognosis of cholangiocarcinoma based on RNA-seq data and in vitro experiments (BioMed Research International, 2020)

🏅 Consultancy and Industry Projects

Dr. Yao has been a key participant in national research projects, including collaborations with Beijing Sino Biological Inc. to develop PD-L2 targeted antibody fragments. This partnership underscores Dr. Yao’s commitment to translating research into practical medical applications.

📖 Editorial Appointments and Professional Memberships

Dr. Yao serves as a reviewer for the International Wound Journal and the Journal of Cancer. Additionally, Dr. Yao is an active member of the Chinese Nuclear Society and the Beijing Precision Radiation Medicine Society.

🏆 Contributions and Impact

Dr. Yao’s groundbreaking work in developing immune checkpoint PD-L2 targeted radiopharmaceuticals has paved the way for new methods to screen potential beneficiaries of immune checkpoint inhibitor therapy. Innovations include monoclonal antibody tracers 124/125I-ATL2 and 89Zr-DFO-ATL2, as well as PD-L2 targeted antibody fragments and polypeptides, contributing significantly to the field of precision medicine.

📜 Patents and Recognitions

Dr. Yao has published three patents with the China National Intellectual Property Administration and has two more in process. Dr. Yao’s dedication to improving clinical practices is evident through the invention of devices that reduce radiation exposure for experimental personnel.

Publication Top Noted:

Paper Title : Elemene injection combined with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: A meta-analysis
  • Authors: Yuan Yao, Jianjian Chen, Dechao Jiao, Yahua Li, Xueliang Zhou, Xinwei Han
  • Journal: Medicine
  • Year: 2019
  • Citations: 11

 

Paper Title : Palliative local treatment of bone metastases by 125I seed brachytherapy under DynaCT guidance: single-center experience
  • Authors:Yuan uan Yao, Zhaonan Li, Dechao Jiao, Xueliang Zhou, Jing Li, Xinwei Han
  • Journal: Diagnostic and Interventional Radiology
  • Year :2021
  • Citations:4
Paper Title : Role of LncRNAs in the epithelial-mesenchymal transition in hepatocellular carcinoma
  • Authors:Yuan Yao, Jing Li, Zhaonan Li, Xinwei Han
  • Journal: Frontiers in oncology
  • Year: 2021
  • Citations: 9
Paper Title :125I seeds inhibit proliferation and promote apoptosis in cholangiocarcinoma cells by regulating the AGR2-mediated p38 MAPK pathway
  • Authors:   Xueliang Zhou, Wenguang Zhang, Mengmeng Dou, Zhaonan Li, Zaoqu Liu, Jing Li, Chuan Tian, Yuan Yao, Chaoyan Wang, Yahua Li, Pengfei Chen, Xinwei Han, Dechao Jiao
  • Journal: Cancer Letters
  • Year: 2022
  • Citations: 12
Paper Title :Intraoperative cone beam computed tomography of tracheal stenting for stenosis and fistula diseases: a retrospective cohort study
  • Authors: Jing Li, Kaihao Xu, Zhaonan Li, Yahua Li, Xueliang Zhou, Juanfang Liu, Yuan Yao, Zaoqu Liu, De-Chao Jiao, Xinwei Han
  • Journal: Quantitative Imaging in Medicine and Surgery
  • Year: 2022
  • Citations: 2